Brian Michael Parks: Final Debarment Order, 8264-8265 [2022-03098]
Download as PDF
8264
Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES1
report, please visit https://www.fda.gov/
media/154873/download.
III. Participating in the Public Meeting
Registration: To register for the public
meeting, please visit the following
website: https://pdufa-hrassessment.eventbrite.com. Please
provide complete contact information
for each attendee, including name, title,
affiliation, address, email, and
telephone.
Registration is free and based on
space availability, with priority given to
early registrants. Persons interested in
attending this public meeting must
register by March 14, 2022, 11:59 p.m.
Eastern Time. We will let registrants
know if registration closes before the
day of the public meeting.
If you need special accommodations
due to a disability, please contact
Patricia Stewart (see FOR FURTHER
INFORMATION CONTACT) no later than
March 8, 2022.
Requests for Oral Presentations:
During online registration, you may
indicate if you wish to present during a
public comment session, and which
topic(s) you wish to address. We will do
our best to accommodate requests to
make public comments. Individuals and
organizations with common interests are
urged to consolidate or coordinate their
presentations and request time for a
joint presentation. Following the close
of registration, we will determine the
amount of time allotted to each
presenter and the approximate time
each oral presentation is to begin, and
will select and notify participants by
March 11, 2022. All requests to make
oral presentations must be received by
March 8, 2022, 11:59 p.m. Eastern Time.
If selected for presentation, any
presentation materials must be emailed
to Patricia Stewart (see FOR FURTHER
INFORMATION CONTACT) no later than
March 11, 2022. No commercial or
promotional material will be permitted
to be presented at the public meeting.
Streaming Webcast of the public
meeting: The webcast for this public
meeting is accessible at https://pdufahr-assessment.eventbrite.com.
If you have never attended a Connect
Pro event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. FDA has
verified the website addresses in this
document, as of the date this document
publishes in the Federal Register, but
websites are subject to change over time.
Transcripts: Please be advised that as
soon as a transcript of the public
meeting is available, it will be accessible
VerDate Sep<11>2014
17:54 Feb 11, 2022
Jkt 256001
at https://www.regulations.gov. It may
be viewed at the Dockets Management
Staff (see ADDRESSES).
Dated: February 9, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–03097 Filed 2–11–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0304]
Brian Michael Parks: Final Debarment
Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (FD&C Act) debarring
Brian Michael Parks for a period of 5
years from importing or offering for
import any article of food (including
dietary supplements) or drug into the
United States. FDA bases this order on
a finding that Mr. Parks was convicted
of one felony count under Federal law
for distribution of an unapproved new
drug with the intent to defraud and
mislead. The factual basis supporting
Mr. Parks’ conviction, as described
below, is conduct relating to the
importation into the United States of
any food and of any drug or controlled
substance. Mr. Parks was given notice of
the proposed debarment and was given
an opportunity to request a hearing to
show why he should not be debarred.
As of November 17, 2021 (30 days after
receipt of the notice), Mr. Parks had not
responded. Mr. Parks’ failure to respond
and request a hearing constitutes a
waiver of his right to a hearing
concerning this matter.
DATES: This order is applicable February
14, 2022.
ADDRESSES: Submit applications for
termination of debarment to the Dockets
Management Staff, Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, 240–402–
7500, or at https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Jaime Espinosa, Division of Enforcement
(ELEM–4029), Office of Strategic
Planning and Operational Policy, Office
of Regulatory Affairs, Food and Drug
Administration, 12420 Parklawn Dr.,
Rockville, MD 20857, 240–402–8743, or
at debarments@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
I. Background
Section 306(b)(1)(C) of the FD&C Act
(21 U.S.C. 335a(b)(1)(C)) permits FDA to
debar an individual from importing an
article of food or offering such an article
for import into the United States if FDA
finds, as required by section
306(b)(3)(A) of the FD&C Act, that the
individual has been convicted of a
felony for conduct relating to the
importation into the United States of
any food. Section 306(b)(1)(D) of the
FD&C Act permits debarment of an
individual from importing or offering
for import any drug into the United
States if the FDA finds, as required by
section 306(b)(3)(C) of the FD&C Act
that the individual has been convicted
of a felony for conduct relating to the
importation into the United States of
any drug or controlled substance.
On February 16, 2021, Mr. Parks was
convicted, as defined in section
306(l)(1) of the FD&C Act in the U.S.
District Court for the Western District of
Virginia, after his plea of guilty, when
the court entered judgment against him
for the offense of distribution of an
unapproved new drug with the intent to
defraud and mislead, in violation of
sections 301(d) and 303(a)(2) of the
FD&C Act 21 U.S.C. 331(d) and
333(a)(2). The FDA’s finding that
debarment is appropriate is based on the
felony conviction referenced herein.
The factual basis for this conviction is
as follows:
As contained in the information in
Mr. Parks’ case, filed on November 23,
2020, he was the owner and operator of
MedFitRX Inc., later known as MedFit
Sarmacuticals Inc. (collectively referred
to as MedFitRX herein), a purported
sport supplement company based in
North Carolina. MedFitRX imported
Selective Androgen Receptor
Modulators (SARMs) in order to use
them in MedFitRx products. SARMs are
synthetic chemicals designed to mimic
the effects of testosterone and other
anabolic steroids. From approximately
March 2016 to September 2019, Mr.
Parks imported SARMs and other drug
active ingredients from China on
multiple occasions. The drug active
ingredients he imported included MK–
677, S–4, MK–2866, GW–501516, LGD–
4033, and RAD140, among others. In
addition, on or about May 17, 2018, Mr.
Parks sold two MedFitRX products to
undercover FDA Office of Criminal
Investigation agents posing as
consumers. The first product Mr. Parks
sold to these undercover agents, Lucky
SARMS Magical AF, contained the
drugs S–23 and SR9009, which he had
caused to be imported into the United
States. The second product, Estrovert,
E:\FR\FM\14FEN1.SGM
14FEN1
jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices
contained the anabolic steroid
Methyldienolone, a controlled
substance prohibited under the Designer
Steroid Act, 21 U.S.C. 802(41), which
Mr. Parks also caused to be imported
into the United States. Mr. Parks worked
with others to conceal the importation
of these and other unapproved drugs as
they were disguised and misdeclared as
articles of food, specifically ‘‘biscuit mix
powder,’’ ‘‘corn powder,’’ ‘‘grain mix
powder,’’ ‘‘bread mix powder,’’ and
‘‘milk tea powder.’’ Mr. Parks then
included these drug active ingredients
in MedFitRX products, which were
unapproved drugs that he introduced
and delivered for introduction into
interstate commerce. Mr. Parks
knowingly marketed these MedFitRX
products as ‘‘dietary supplements’’ and
‘‘sports supplements’’ to create the
impression they were safe and legal to
use, and otherwise intentionally failed
to include certain drug active
ingredients on the product labels.
As a result of this conviction, FDA
sent Mr. Parks, by certified mail, on
October 12, 2021, a notice proposing to
debar him for a 5-year period from
importing or offering for import any
article of food or drug into the United
States. The proposal was based on a
finding under section 306(b)(1)(C) and
(b)(3)(C) of the FD&C Act that Mr. Parks’
felony conviction of distribution of an
unapproved new drug with the intent to
defraud and mislead constitutes
conduct relating to the importation into
the United States of an article of food
and any drug or controlled substance
because Mr. Parks illegally imported
unapproved drugs into the United
States, working with others to disguise
and misdeclare them as articles of food,
and then distributed those unapproved
drugs to consumers in the United States,
marketing them as ‘‘dietary
supplements’’ and ‘‘sports
supplements.’’ In proposing a
debarment period, FDA weighed the
considerations set forth in section
306(c)(3) of the FD&C Act that it
considered applicable to Mr. Parks’
offense, and concluded that the felony
offense warranted the imposition of a 5year period of debarment.
The proposal informed Mr. Parks of
the proposed debarment and offered
him an opportunity to request a hearing,
providing him 30 days from the date of
receipt of the letter in which to file the
request, and advised him that failure to
request a hearing constituted a waiver of
the opportunity for a hearing and of any
contentions concerning this action. Mr.
Parks received the proposal and notice
of opportunity for a hearing on October
18, 2021. Mr. Parks failed to request a
hearing within the timeframe prescribed
VerDate Sep<11>2014
17:54 Feb 11, 2022
Jkt 256001
by regulation and has, therefore, waived
his opportunity for a hearing and
waived any contentions concerning his
debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant
Commissioner, Office of Human and
Animal Food Operations, under section
306(b)(1)(C) and (b)(3)(C) of the FD&C
Act, under authority delegated to the
Assistant Commissioner, finds that Mr.
Brian Michael Parks has been convicted
of a felony under Federal law for
conduct relating to the importation into
the United States of an article of food
and of a drug or controlled substance,
and that he is subject to a 5-year period
of debarment.
As a result of the foregoing finding,
Mr. Parks is debarred for a period of 5
years from importing or offering for
import articles of food or any drug or
controlled substances into the United
States, applicable (see DATES). Pursuant
to section 301(cc) of the FD&C Act, the
importing or offering for import into the
United States of an article of food or of
any drug or controlled substance by,
with the assistance of, or at the direction
of Mr. Parks is a prohibited act.
Any application by Mr. Parks for
termination of debarment under section
306(d)(1) of the FD&C Act should be
identified with Docket No. FDA–2021–
N–0304 and sent to the Dockets
Management Staff (see ADDRESSES). The
public availability of information in
these submissions is governed by 21
CFR 10.20.
Publicly available submissions will be
placed in the docket and will be
viewable at https://www.regulations.gov
or at the Dockets Management Staff (see
ADDRESSES) between 9 a.m. and 4 p.m.,
Monday through Friday, 240–402–7500.
Dated: February 8, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–03098 Filed 2–11–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Meeting of the Advisory Committee on
Infant and Maternal Mortality (Formerly
the Advisory Committee on Infant
Mortality)
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
8265
In accordance with the
Federal Advisory Committee Act, this
notice announces that the Advisory
Committee on Infant and Maternal
Mortality (ACIMM or Committee) has
scheduled a public meeting. Information
about ACIMM and the agenda for this
meeting can be found on the ACIMM
website at https://www.hrsa.gov/
advisory-committees/infant-mortality/
index.html.
SUMMARY:
March 15, 2022, 12:00 p.m. to
4:00 p.m. Eastern Time and March 16,
2022, 12:00 p.m. to 4:00 p.m. Eastern
Time.
DATES:
This meeting will be held
virtually via webinar. The webinar link
and log-in information will be available
at the ACIMM website before the
meeting: https://www.hrsa.gov/advisorycommittees/infant-mortality/.
FOR FURTHER INFORMATION CONTACT:
Anne Leitch, Maternal and Child Health
Bureau, HRSA, 5600 Fishers Lane,
Rockville, Maryland 20857; 301–443–
1321; or SACIM@hrsa.gov.
SUPPLEMENTARY INFORMATION: ACIMM is
authorized by section 222 of the Public
Health Service Act (42 U.S.C. 217a), as
amended. The Committee is governed
by provisions of Public Law 92–463, as
amended, (5 U.S.C. App. 2), which sets
forth standards for the formation and
use of Advisory Committees.
The ACIMM advises the Secretary of
Health and Human Services (Secretary)
on department activities, partnerships,
policies, and programs directed at
reducing infant mortality, maternal
mortality and severe maternal
morbidity, and improving the health
status of infants and women before,
during, and after pregnancy. The
Committee provides advice on how to
coordinate federal, state, local, tribal,
and territorial governmental efforts
designed to improve infant mortality,
related adverse birth outcomes, and
maternal health, as well as influence
similar efforts in the private and
voluntary sectors. The Committee
provides guidance and
recommendations on the policies,
programs, and resources required to
address the disparities and inequities in
infant mortality, related adverse birth
outcomes and maternal health
outcomes, including maternal mortality
and severe maternal morbidity. With its
focus on underlying causes of the
disparities and inequities seen in birth
outcomes for women and infants, the
Committee advises the Secretary on the
health, social, economic, and
environmental factors contributing to
the inequities and proposes structural,
policy, and/or systems level changes.
ADDRESSES:
E:\FR\FM\14FEN1.SGM
14FEN1
Agencies
[Federal Register Volume 87, Number 30 (Monday, February 14, 2022)]
[Notices]
[Pages 8264-8265]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03098]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0304]
Brian Michael Parks: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring
Brian Michael Parks for a period of 5 years from importing or offering
for import any article of food (including dietary supplements) or drug
into the United States. FDA bases this order on a finding that Mr.
Parks was convicted of one felony count under Federal law for
distribution of an unapproved new drug with the intent to defraud and
mislead. The factual basis supporting Mr. Parks' conviction, as
described below, is conduct relating to the importation into the United
States of any food and of any drug or controlled substance. Mr. Parks
was given notice of the proposed debarment and was given an opportunity
to request a hearing to show why he should not be debarred. As of
November 17, 2021 (30 days after receipt of the notice), Mr. Parks had
not responded. Mr. Parks' failure to respond and request a hearing
constitutes a waiver of his right to a hearing concerning this matter.
DATES: This order is applicable February 14, 2022.
ADDRESSES: Submit applications for termination of debarment to the
Dockets Management Staff, Food and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, or at https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of
Enforcement (ELEM-4029), Office of Strategic Planning and Operational
Policy, Office of Regulatory Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD 20857, 240-402-8743, or at
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(C) of the FD&C Act (21 U.S.C. 335a(b)(1)(C))
permits FDA to debar an individual from importing an article of food or
offering such an article for import into the United States if FDA
finds, as required by section 306(b)(3)(A) of the FD&C Act, that the
individual has been convicted of a felony for conduct relating to the
importation into the United States of any food. Section 306(b)(1)(D) of
the FD&C Act permits debarment of an individual from importing or
offering for import any drug into the United States if the FDA finds,
as required by section 306(b)(3)(C) of the FD&C Act that the individual
has been convicted of a felony for conduct relating to the importation
into the United States of any drug or controlled substance.
On February 16, 2021, Mr. Parks was convicted, as defined in
section 306(l)(1) of the FD&C Act in the U.S. District Court for the
Western District of Virginia, after his plea of guilty, when the court
entered judgment against him for the offense of distribution of an
unapproved new drug with the intent to defraud and mislead, in
violation of sections 301(d) and 303(a)(2) of the FD&C Act 21 U.S.C.
331(d) and 333(a)(2). The FDA's finding that debarment is appropriate
is based on the felony conviction referenced herein. The factual basis
for this conviction is as follows:
As contained in the information in Mr. Parks' case, filed on
November 23, 2020, he was the owner and operator of MedFitRX Inc.,
later known as MedFit Sarmacuticals Inc. (collectively referred to as
MedFitRX herein), a purported sport supplement company based in North
Carolina. MedFitRX imported Selective Androgen Receptor Modulators
(SARMs) in order to use them in MedFitRx products. SARMs are synthetic
chemicals designed to mimic the effects of testosterone and other
anabolic steroids. From approximately March 2016 to September 2019, Mr.
Parks imported SARMs and other drug active ingredients from China on
multiple occasions. The drug active ingredients he imported included
MK-677, S-4, MK-2866, GW-501516, LGD-4033, and RAD140, among others. In
addition, on or about May 17, 2018, Mr. Parks sold two MedFitRX
products to undercover FDA Office of Criminal Investigation agents
posing as consumers. The first product Mr. Parks sold to these
undercover agents, Lucky SARMS Magical AF, contained the drugs S-23 and
SR9009, which he had caused to be imported into the United States. The
second product, Estrovert,
[[Page 8265]]
contained the anabolic steroid Methyldienolone, a controlled substance
prohibited under the Designer Steroid Act, 21 U.S.C. 802(41), which Mr.
Parks also caused to be imported into the United States. Mr. Parks
worked with others to conceal the importation of these and other
unapproved drugs as they were disguised and misdeclared as articles of
food, specifically ``biscuit mix powder,'' ``corn powder,'' ``grain mix
powder,'' ``bread mix powder,'' and ``milk tea powder.'' Mr. Parks then
included these drug active ingredients in MedFitRX products, which were
unapproved drugs that he introduced and delivered for introduction into
interstate commerce. Mr. Parks knowingly marketed these MedFitRX
products as ``dietary supplements'' and ``sports supplements'' to
create the impression they were safe and legal to use, and otherwise
intentionally failed to include certain drug active ingredients on the
product labels.
As a result of this conviction, FDA sent Mr. Parks, by certified
mail, on October 12, 2021, a notice proposing to debar him for a 5-year
period from importing or offering for import any article of food or
drug into the United States. The proposal was based on a finding under
section 306(b)(1)(C) and (b)(3)(C) of the FD&C Act that Mr. Parks'
felony conviction of distribution of an unapproved new drug with the
intent to defraud and mislead constitutes conduct relating to the
importation into the United States of an article of food and any drug
or controlled substance because Mr. Parks illegally imported unapproved
drugs into the United States, working with others to disguise and
misdeclare them as articles of food, and then distributed those
unapproved drugs to consumers in the United States, marketing them as
``dietary supplements'' and ``sports supplements.'' In proposing a
debarment period, FDA weighed the considerations set forth in section
306(c)(3) of the FD&C Act that it considered applicable to Mr. Parks'
offense, and concluded that the felony offense warranted the imposition
of a 5-year period of debarment.
The proposal informed Mr. Parks of the proposed debarment and
offered him an opportunity to request a hearing, providing him 30 days
from the date of receipt of the letter in which to file the request,
and advised him that failure to request a hearing constituted a waiver
of the opportunity for a hearing and of any contentions concerning this
action. Mr. Parks received the proposal and notice of opportunity for a
hearing on October 18, 2021. Mr. Parks failed to request a hearing
within the timeframe prescribed by regulation and has, therefore,
waived his opportunity for a hearing and waived any contentions
concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant Commissioner, Office of Human and Animal
Food Operations, under section 306(b)(1)(C) and (b)(3)(C) of the FD&C
Act, under authority delegated to the Assistant Commissioner, finds
that Mr. Brian Michael Parks has been convicted of a felony under
Federal law for conduct relating to the importation into the United
States of an article of food and of a drug or controlled substance, and
that he is subject to a 5-year period of debarment.
As a result of the foregoing finding, Mr. Parks is debarred for a
period of 5 years from importing or offering for import articles of
food or any drug or controlled substances into the United States,
applicable (see DATES). Pursuant to section 301(cc) of the FD&C Act,
the importing or offering for import into the United States of an
article of food or of any drug or controlled substance by, with the
assistance of, or at the direction of Mr. Parks is a prohibited act.
Any application by Mr. Parks for termination of debarment under
section 306(d)(1) of the FD&C Act should be identified with Docket No.
FDA-2021-N-0304 and sent to the Dockets Management Staff (see
ADDRESSES). The public availability of information in these submissions
is governed by 21 CFR 10.20.
Publicly available submissions will be placed in the docket and
will be viewable at https://www.regulations.gov or at the Dockets
Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday
through Friday, 240-402-7500.
Dated: February 8, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-03098 Filed 2-11-22; 8:45 am]
BILLING CODE 4164-01-P